Beta Drugs Intrinsic Value
Beta Drugs (BETA) median intrinsic value is ₹747.78 from 9 valuation models (range ₹394–₹1065), vs current price ₹1400.70 — -46.6% downside (Trading Above Calculated Value), margin of safety -87.3%. For current market price and key ratios, visit BETA stock live price.
BETA Valuation Methods Summary — DCF, Graham Number & P/E
Beta Drugs intrinsic value across 9 models vs current price ₹1400.70 — upside/downside and value range per method. Browse BETA financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1064.80 | ₹851.84 - ₹1277.76 | -24.0% | EPS: ₹48.40, Sector P/E: 22x |
| Book Value Method | asset | ₹394.00 | ₹354.60 - ₹433.40 | -71.9% | Book Value/Share: ₹197.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹848.00 | ₹763.20 - ₹932.80 | -39.5% | Revenue/Share: ₹424.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹960.00 | ₹864.00 - ₹1056.00 | -31.5% | EBITDA: ₹96.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹560.28 | ₹448.22 - ₹672.34 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹420.21 | ₹378.19 - ₹462.23 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹747.78 | ₹673.00 - ₹822.56 | -46.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹768.00 | ₹691.20 - ₹844.80 | -45.2% | ROE: 24.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹420.21 | ₹378.19 - ₹462.23 | -70.0% | EPS: ₹48.40, BVPS: ₹197.00 |
BETA Intrinsic Value vs Market Price — All Valuation Models
Beta Drugs fair value range ₹394–₹1065 vs current market price ₹1400.70 across 9 valuation models. Compare with BETA intrinsic value calculation to assess whether the stock is under or overvalued.
BETA Intrinsic Value Analysis — Undervalued or Overvalued?
Beta Drugs median intrinsic value ₹747.78, current price ₹1400.70 — Trading Above Calculated Value by 46.6%, margin of safety -87.3%.
What is the intrinsic value of BETA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Beta Drugs (BETA) is ₹747.78 (median value). With the current market price of ₹1400.70, this represents a -46.6% variance from our estimated fair value.
The valuation range spans from ₹394.00 to ₹1064.80, indicating ₹394.00 - ₹1064.80.
Is BETA undervalued or overvalued?
Based on our multi-method analysis, Beta Drugs (BETA) appears to be trading above calculated value by approximately 46.6%.
BETA Financial Health — Key Ratios vs Industry Benchmarks
Beta Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.43 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 24.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.97x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BETA Cash Flow Quality — Operating & Free Cash Flow
Beta Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹36 Cr | ₹18 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹31 Cr | ₹24 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹23 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹30 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹19 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |